Journal: Cancer research

Article Title: Nicotinamide mononucleotide prevents cisplatin-induced cognitive impairments

doi: 10.1158/0008-5472.CAN-20-3290

Figure Lengend Snippet: A, Schematic diagram of experimental design for cisplatin or vehicle administration. B, Representative platinum (Pt) distribution images of hippocampus sub-regions (dentate gyrus, CA1 and CA3) and prefrontal cortex from vehicle and cisplatin-treated mice using Imaging Mass Cytometry (IMC). Adult female mice were intraperitoneally injected with vehicle or cisplatin, and sacrificed at 2 and 5 weeks after the final vehicle or cisplatin injection. All scale bars: 100 μm for dentate gyrus, CA1, CA3, and prefrontal cortex.

Article Snippet: To induce cognitive dysfunction in mice, we used the platinum-based compound cisplatin (Fresenius Kabi, Cat# 100351), which has been reported to accumulate in significant concentrations in patient brains ( 17 ).

Techniques: Imaging, Mass Cytometry, Injection

Journal: Cancer research

Article Title: Nicotinamide mononucleotide prevents cisplatin-induced cognitive impairments

doi: 10.1158/0008-5472.CAN-20-3290

Figure Lengend Snippet: A, Reduction in cellular NAD+ levels by cisplatin administration in adult mouse hippocampus (Hip), striatum (Str), and cerebellum (CB). B, Schematic diagram of experimental design for NMN and cisplatin administrations, and follow up behavior and cellular analysis presented in Fig. 2, and ​and3A3A and ​andB.B. C, Schematic diagrams of the novel object recognition (NOR) task. D, Left: Time exploring the familiar objects on Day 2. While there was a slight increase in mice treated with NMN alone, there were no major differences detected in time spent exploring the two familiar objects, indicating a lack of location preference. Right: Time exploring the objects in familiar and novel locations on Day 3 was recorded. n = 9–10 mice. E, Average latency to find the hidden platform during training, and average number of target zone crossings where the hidden platform was previously located during the probe test in Morris water maze (MWM) test. F, Representative swimming paths during the probe test (Day 5). G, Increase in cellular NAD+ levels by NMN in combination with cisplatin treatment in the adult mouse hippocampus (Hip) and cerebellum (CB). The number associated with bar graphs indicates the number of mice tested. Circles within each bar in graphs represent an individual mouse. Data represent mean ± SEM. Unpaired, two-tailed Student’s t-test (G) with Welch’s correction (A), paired, two-tailed Student’s t-test (D), and two-way ANOVA followed by Tukey’s post-hoc corrections (F). *: P < 0.05, **: P < 0.01, ***: P < 0.001, n.s.: not significant.

Article Snippet: To induce cognitive dysfunction in mice, we used the platinum-based compound cisplatin (Fresenius Kabi, Cat# 100351), which has been reported to accumulate in significant concentrations in patient brains ( 17 ).

Techniques: Two Tailed Test

Journal: Cancer research

Article Title: Nicotinamide mononucleotide prevents cisplatin-induced cognitive impairments

doi: 10.1158/0008-5472.CAN-20-3290

Figure Lengend Snippet: A, Nicotinamide phosphoribosyltransferase (Nampt)-mediated nicotinamide adenine dinucleotide (NAD+) biosynthetic pathways. Nampt converts nicotinamide to nicotinamide mononucleotide (NMN), which is subsequently converted into NAD+. NAD+ serves as a co-substrate for NAD+-dependent Sirtuin enzymes such as Sirt1 and Sirt2. Nicotinamide mononucleotide adenylyltransferase (Nmnat) catalyzes NAD+ synthesis. B, Representative western blots and densitometry quantification in adult mouse hippocampus lysates. n = 10 mice/group for Nampt, n = 15 mice/group for Sirt1 and Sirt2. C, Left: Schematic diagram of experimental design for the Cre- or control-retroviral injection and cisplatin administration in adult floxed Nampt overexpression mice (Nampt OXf/+). Right: Representative images of GFP+ aborn neurons and cumulative distribution plots of total dendrite length of adult-born neurons in each group. Scale bar: 50 μm. Each symbol represents data GFP+ neurons. D, Water maze test; Average latency to find the hidden platform during the training periods (left), average number of target zone crossings where the hidden platform was previously located (middle) and latency to reach platform zone during the probe test (right). Circles within each bar in graphs represent an individual mouse. Data represent mean ± SEM. Unpaired, two-tailed Student’s t-test with Welch’s correction (B), Kolmogorov-Smirnov test (C) and two-way ANOVA followed by Tukey’s post-hoc correction (D). *: P < 0.05, **: P < 0.01, ***: P < 0.001. n.s.: not significant.

Article Snippet: To induce cognitive dysfunction in mice, we used the platinum-based compound cisplatin (Fresenius Kabi, Cat# 100351), which has been reported to accumulate in significant concentrations in patient brains ( 17 ).

Techniques: Western Blot, Injection, Over Expression, Two Tailed Test

Journal: Cancer research

Article Title: Nicotinamide mononucleotide prevents cisplatin-induced cognitive impairments

doi: 10.1158/0008-5472.CAN-20-3290

Figure Lengend Snippet: A, Schematic diagram of the differentiation procedure. B, Representative confocal images for Tuj-1 (neuron markers), CTIP2 and TBR1 (cortical neuron markers), VGLUT1 (excitatory neuron marker), S100β (astrocyte marker), Olig2 (oligodendrocyte marker) and Iba-1 (microglia marker). Note that the majority of iPSCs were differentiated into cortical excitatory neurons, but not glial cells. All scale bars: 50 μm. C, Reduction in neuronal NAD+ levels by cisplatin administration in human cortical neurons. n = 4 wells/each treatment group. D, Left: Representative images of MAP2 (neuron marker) and DAPI (nuclei marker). Scale bar: 50 μm. Right: Quantification of the neurite outgrowth in each treatment group. Each circle represents an individual well. Data represents mean ± SEM. One-way ANOVA followed by Dunnett’s (C) and two-way ANOVA followed by Tukey’s post-hoc corrections (D). **: P < 0.01, ***: P < 0.001.

Article Snippet: To induce cognitive dysfunction in mice, we used the platinum-based compound cisplatin (Fresenius Kabi, Cat# 100351), which has been reported to accumulate in significant concentrations in patient brains ( 17 ).

Techniques: Marker

Journal: PLoS ONE

Article Title: Mir-34a Mimics Are Potential Therapeutic Agents for p53-Mutated and Chemo-Resistant Brain Tumour Cells

doi: 10.1371/journal.pone.0108514

Figure Lengend Snippet: ( A, B ) D283-MED, MHH-Med1 and MEB-Med8A cells were treated with [20 µM] etoposide for indicated time points and levels of miR-34a (A) and Mdm2 mRNA ( B ) were assessed by real time qPCR. Results were normalised to cyclophilin A and fold changes relative to the untreated control. See also for a DMSO control. ( C ) D283-MED cells were transfected with siRNA directed to p53 or with non-specific siRNA as a negative control for 48 hours prior to etoposide treatment. The levels of miR-34a were assessed by qPCR as in (A). Data shown are the mean ± S.E.M of three independent experiments. (A–C) Kruskal-Wallis ANOVA test was performed (*indicates p<0.05). ( D – F ) Cell viability of D283-MED, MHH-Med1 and MEB-Med8A was measured by MTS assay upon treatment at indicated time points. ( D ) Etoposide [20 µM] ( E ) cisplatin [5 µM] ( F ) methrotrexate [5 µM]. The percentages of viable cells were relative to the untreated control. See also for a vehicle DMSO control on cell death. Data shown are the mean ± S.E.M of three independent experiments.

Article Snippet: Cisplatin (cat# 440-040) and metothrexate (cat# 440-045) were from Enzo Life Sciences UK Ltd (Exeter, UK).

Techniques: Transfection, Negative Control, MTS Assay

Journal: Oncology Letters

Article Title: Inhibition effects of Yuxiao San combined with cisplatin on transplanted tumor growths via upregulation of nm-23 and downregulation of K-ras in Lewis lung cancer mice

doi: 10.3892/ol.2018.9673

Figure Lengend Snippet: Effect of Yuxiao San on Lewis lung cancer tumor growth and progression in C57BL/6 mice (mean ± standard deviation, n=10 per group).

Article Snippet: Cisplatin (cat. no. 2A1A1401002A) was purchased from Qilu Pharmaceutical Co., Ltd. (Hainan, China).

Techniques: Standard Deviation, Inhibition

Journal: Oncology Letters

Article Title: Inhibition effects of Yuxiao San combined with cisplatin on transplanted tumor growths via upregulation of nm-23 and downregulation of K-ras in Lewis lung cancer mice

doi: 10.3892/ol.2018.9673

Figure Lengend Snippet: Effect of Yuxiao San on pulmonary surface metastatic nodules of Lewis lung carcinoma in C57BL/6 mice (mean ± standard deviation, n=10 per group).

Article Snippet: Cisplatin (cat. no. 2A1A1401002A) was purchased from Qilu Pharmaceutical Co., Ltd. (Hainan, China).

Techniques: Standard Deviation, Inhibition

Journal: Oncology Letters

Article Title: Inhibition effects of Yuxiao San combined with cisplatin on transplanted tumor growths via upregulation of nm-23 and downregulation of K-ras in Lewis lung cancer mice

doi: 10.3892/ol.2018.9673

Figure Lengend Snippet: Comparison of groups of the mean absorbance of K-ras and nm23 (mean ± standard deviation, n=10 per group).

Article Snippet: Cisplatin (cat. no. 2A1A1401002A) was purchased from Qilu Pharmaceutical Co., Ltd. (Hainan, China).

Techniques: Comparison, Standard Deviation

Journal: Oncology Letters

Article Title: Inhibition effects of Yuxiao San combined with cisplatin on transplanted tumor growths via upregulation of nm-23 and downregulation of K-ras in Lewis lung cancer mice

doi: 10.3892/ol.2018.9673

Figure Lengend Snippet: Expression of K-ras and nm-23 by western blotting. (A) Western blotting and (B) quantification and statistical analysis. *P<0.01 vs. model group and #P<0.01 vs. cisplatin group. nm-23, nucleoside diphosphate kinase.

Article Snippet: Cisplatin (cat. no. 2A1A1401002A) was purchased from Qilu Pharmaceutical Co., Ltd. (Hainan, China).

Techniques: Expressing, Western Blot

Journal: Oncology Letters

Article Title: Inhibition effects of Yuxiao San combined with cisplatin on transplanted tumor growths via upregulation of nm-23 and downregulation of K-ras in Lewis lung cancer mice

doi: 10.3892/ol.2018.9673

Figure Lengend Snippet: mRNA expression levels of K-ras and nm-23 using reverse transcription-quantitative polymerase chain reaction. *P<0.01 vs. model group and #P<0.01 vs. cisplatin group. nm-23, nucleoside diphosphate kinase.

Article Snippet: Cisplatin (cat. no. 2A1A1401002A) was purchased from Qilu Pharmaceutical Co., Ltd. (Hainan, China).

Techniques: Expressing, Reverse Transcription, Real-time Polymerase Chain Reaction

Journal: Biomedicines

Article Title: GSK2606414 Sensitizes ABCG2-Overexpressing Multidrug-Resistant Colorectal Cancer Cells to Chemotherapeutic Drugs

doi: 10.3390/biomedicines11113103

Figure Lengend Snippet: Summary of the IC 50 values. The fold reversal value was calculated by dividing the IC 50 of each drug in S1-M1-80 vector or S1-M1-80 sgABCG2 cells in the absence of inhibitors by that in the presence of inhibitors. ** p < 0.01 vs. the corresponding group.

Article Snippet: Cisplatin (Cat. No.: AA1A8019B) was obtained from Qilu Pharmaceutical Co. (Jinan, China).

Techniques: Plasmid Preparation